10-Q quarterly report · filed Oct 30, 2026

Thermo Fisher Scientific (TMO) Q3 2026 10-Q Quarterly Report

Short answer

Thermo Fisher Scientific (TMO) filed its Q3 2026 10-Q quarterly report on Oct 30, 2026 for the quarter ended Sep 26, 2026. Quarterly revenue was $12.1B (up 9.1% year over year) with net income of $1.7B.

Q3 2026 key financials · XBRL

Revenue
$12.1B
+9.1% YoY · +1.2% QoQ
Net income
$1.7B
+6.5% YoY · −0.9% QoQ
Operating margin
18.6%
EPS (diluted)
$4.65
+8.9% YoY · −0.4% QoQ

Source: XBRL data from the Thermo Fisher Scientific (TMO) Q3 2026 10-Q on SEC EDGAR. USD.

Thermo Fisher Scientific Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $12,137M, up from $11,122M YoY; Laboratory Products and Biopharma Services led contributions
  • GAAP operating margin 18.6% vs 17.4%; adjusted margin 24.5% vs 23.3%
  • Best segment: Laboratory Products and Biopharma Services revenue $6,863M vs $5,970M, margin 15.5% vs 14.5%
  • Worst segment: Specialty Diagnostics revenue $1,098M vs $1,174M; margin 31.0% vs 27.4%
  • Cash $5,461M vs $9,852M; operating cash flow $5,867M, free cash flow $4,618M, acquisitions $8.88B

Risk Factors

  • No material changes identified from the December 31, 2025 Form 10-K
  • Carried-forward risks remain detailed in the company’s 2025 Annual Report

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Thermo Fisher Scientific quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.